D.E. Shaw & Co
ELVN icon

D.E. Shaw & Co’s Enliven Therapeutics ELVN Stock Holding History

D.E. Shaw & Co’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.59M Buy
+193,531
New +$5.36M ﹤0.01% 1845
2022
Q1 		– Sell
-20,967
Closed -$189K – 5630
2021
Q4 		$189K Buy
20,967
+5,469
+35% +$71.7K ﹤0.01% 4900
2021
Q3 		$253K Buy
+15,498
New +$322K ﹤0.01% 4451

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co's ELVN Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 193,531 shares worth $7.59M. The stake represents ﹤0.01% of the portfolio and ranks #1845 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in ELVN as recently as Q4 2021.

D.E. Shaw & Co first reported a position in ELVN in Q3 2021 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • D.E. Shaw & Co held 193,531 shares of Enliven Therapeutics worth $7.59M as of Q1 2026.
  • Enliven Therapeutics was a new D.E. Shaw & Co position in Q1 2026.
  • Enliven Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1845 holding.
  • D.E. Shaw & Co first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.